Angiogenesis plays an important role in the pathogenesis of both pulmonary arterial hypertension (PAH) and chronic myeloproliferative disorders (CMPDs). 1, 2 The WHO classification of pulmonary hypertension includes CMPDs as diseases associated with PAH development 1 and, according to the literature, pulmonary hypertension affects between 13 and 48% of patients with myeloproliferative diseases. It has been suggested that this comorbidity has a multifactorial pathobiological origin, including the presence of pulmonary myeloid metaplasia, the obstruction of pulmonary vessels by circulating megakaryocytes, smooth muscle hyperplasia due to platelet-derived growth factor (PDGF), and thromboembolic events. 3, 4 However, little is known about the origin of the association, and the possible pathogenetic link between CMPDs and PAH has not yet been studied.
We investigated this association in primary myelofibrosis (PMF) diagnosed on the basis of the WHO classification. 5 The study group consisted of 36 patients being followed up at our institution: 22 with PMF, 7 with PMF developing from polycythemia vera and 7 with PMF progressing from essential thrombocythemia. Their clinical characteristics are summarized in Table 1 . The control groups consisted of 10 healthy subjects (controls) and 10 patients with pulmonary hypertension due to other causes (S-PH).
The Mann-Whitney U test was used for between-group comparisons, and Spearman's correlation coefficient was computed to evaluate the associations between variables.
Systolic pulmonary artery pressure (sPAP) was evaluated in all patients by means of color Doppler echocardiography and PAH was defined as an sPAPX35 mm Hg. Secondary causes of sPAP elevation were excluded by means of echocardiography, highresolution lung CT scan, arterial blood gas evaluations, pulmonary function tests with CO diffusion and lung perfusion scintigraphy. PAH was found in 13 patients (36%), 6 of whom had moderate pulmonary hypertension (sPAP 45-55 mm Hg); in none of the cases, the sPAP elevation was due to cardiopulmonary or thromboembolic diseases: the median pO 2 was 88 mm Hg (range: 82-96) and the SO 2 97% (range: 96-99), and the other examinations provided no relevant results.
Three patients with PAH-related PMF complained of symptoms attributable to PAH, such as dyspnea on exertion or fatigue. They had slightly lower median hemoglobin levels than the PMF patients as a whole (10.1 vs 11.8 g dl À1 , P ¼ NS). The presence of PAH did not correlate with disease duration or any of the clinical features listed in Table 1 .
In addition to the above clinical analysis, we also evaluated laboratory parameters related to angiogenesis and PAH development. Peripheral blood levels of endothelial progenitor cells (EPCs, defined as CD45
À , CD34 þ and CD133 þ ), circulating endothelial cells (CECs, defined as CD45 À , CD31 þ and P1H12 þ ) and CD34 þ cells (defined as CD45 þ and CD34 þ ) were quantified by flow cytometry. Serum concentrations of VEGF, endothelin-1 (ET-1), TGFb, PDGF AB and E-selectin were assessed by means of commercial enzyme-linked immunosorbent assays. Bone marrow microvessel density (MVD) was evaluated using the 'hot spots' method on 33 biopsy specimens of the PMF patients, and compared with the figures obtained in 16 healthy controls.
Endothelial progenitor cells are mobilizable bone marrowderived stem cells that can home into sites of active angiogenesis. However, the magnitude and physiological importance of this property is currently debated. Other lines of evidence also show that a large number of EPCs with enhanced functionality may have protective properties against endothelium-dependent diseases such as coronary artery diseases. 6 In addition, it has recently been reported that the number of circulating EPCs is increased in PMF, and this was suggested as being associated with its pro-angiogenic phenotype. 7 The median number of EPCs in the controls and S-PH patients was similarly low (0.29 Â 10 6 l À1 (0.13-1.71) and 0.41 Â 10 6 l
À1
(0-0.56)), but it was significantly higher in the PMF patients (0.77 Â 10 6 l À1 (0-4.31); P ¼ 0.02 vs controls; P ¼ 0.01 vs S-PH; Figure 1b ). The PMF patients without PAH had more EPCs than those with sPAPX35 mm Hg (0.94 Â 10 6 l À1 (0.13-4.31) vs 0.43 Â 10 6 l À1 (0-2.46); P ¼ 0.009; Figure 1c) , and there was a negative correlation between the EPC counts and sPAP levels Letters to the Editor (Spearman P ¼ 0.01, r ¼ À0.42; Figure 1d ). It has previously been observed that EPCs have a protective effect on endothelium 6 and, in particular, on pulmonary endothelium in a rat model of pulmonary hypertension. 8 The lower EPC levels in our PMF patients with PAH support the idea that a relative EPC deficiency can lead to the development of PAH.
Increased peripheral blood CEC levels have been documented in many human diseases characterized by endothelial damage and dysfunction, including pulmonary hypertension, as well as in conditions such as neoplasia associated with enhanced angiogenesis.
We find that the median number of CECs was significantly higher in our PMF patients than in the controls (16. (0.31-165.66); P ¼ NS). To investigate the relationship between pulmonary pressure and endothelial cell shedding further, we also counted CECs in the S-PH patients and found they were significantly more than in the controls (44.3 Â 10 6 l À1 (5-59.8); P ¼ 0.009; Figure 1a ), but not significantly more than in either of the PMF subgroups.
We have previously described high CEC levels in patients with PAH and systemic sclerosis (a disease characterized by overt vascular damage) in whom we found that the number of CECs positively related to sPAP levels and correlated with the plasma levels of E-selectin. 9 Unlike those in patients with systemic sclerosis, the CEC levels in our PMF patients were not associated with the presence of PAH and did not change with disease progression. Furthermore, E-selectin levels were not altered in the patients with PMF-associated PAH. The high CEC count probably reflects the enhanced angiogenesis characterizing the disease rather than direct vascular damage. Extremely low levels of ET-1 were found in both the PMF patients and controls (0 pg ml À1 (0-5.9) and 0 pg ml À1 (0-1.5); P ¼ NS, data not shown), with no difference between the patients with and without PAH. On the other hand, the S-PH patients had significantly higher levels (30.6 pg ml À1 (0-117); Pp0.01 vs both of the other groups; data not shown). ET-1 is a potent vasoconstrictor whose levels are increased in PAH, and ET receptor antagonism is an effective therapy. However, they are uniformly low in patients affected by PMF-related PAH, thus indicating that ET-1 might not play a key role in this setting.
There were no significant results regarding PDGF or TGFb levels.
The median VEGF level was significantly higher in the PMF patients (1484 pg ml À1 (267-2369)) than in the controls (260 pg ml À1 (69-303); P ¼ 0.006) or S-PH subjects (399 pg ml
(117-840); Po0.001; Figure 2a ) and, among the PMF patients, it was higher in those with PAH than in those without (1850 pg ml
(1151-2306) vs 1037 pg ml
(267-2369); P ¼ 0.03; Figure 2b) .
Similarly, a high MVD value was found in the PMF group in comparison with the controls (56.6 vessels/high-power field (23.2-90) vs 15.2 (2.4-34.4); Po0.0001; Figure 2c) , and the PMF patients with PAH had a higher MVD than those without (66.6 (39.6-90) vs 51.8 (23.2-88); P ¼ 0.006; Figure 2d ). MVD was also associated with marrow cellularity (P ¼ 0.012; data not shown), but not with splenomegaly. 
Distribution of circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) in the three groups (primary myelofibrosis (PMF), controls, S-PH; a and b), and in PMF patients with and without pulmonary arterial hypertension (PAH; c). Relationship between EPCs and systolic pulmonary arterial pressure (sPAP; d).
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These data show that elevated sPAP levels are associated with an enhanced angiogenic status, as evaluated in the periphery and in bone marrow.
As it has previously been reported that EPCs may derive from the neoplastic clone in polycythemia vera and PMF, we tested whether the JAK2 V617F mutation may be associated with a different pro-angiogenic phenotype, but we did not find any differences when we grouped patients on the basis of this characteristic.
The results of this study show that 36% of our PMF patients were affected by PAH, which was rigorously, although noninvasively documented. Despite its high prevalence, the clinical impact of PMF-associated PAH seems to be small as only 3 of our 13 patients complained of symptoms attributable to PAH. This may be explained by the fact that some of the clinical features of PAH, such as dyspnea on exertion or fatigue, may be overshadowed by those related to anemia or the chronic disease itself.
On the other hand, as suggested by a number of case reports, the development of clinically significant PAH may influence the life expectancy of PMF patients. 3, 4 For these reasons, we think that PMF patients with symptoms that may be related to PAH should be more carefully assessed.
As previously reported, we found enhanced angiogenesis in the peripheral blood and bone marrow of our PMF patients as they were characterized by increased bone marrow MVD, serum VEGF levels and circulating EPCs. Furthermore, we also found that the CEC count is high in PMF and that sPAP levels significantly affect the parameters of angiogenesis. Our PAHpositive patients had higher MVD and VEGF levels (suggesting the presence of a pro-angiogenic phenomenon), a negative correlation between EPCs and sPAP, and low EPC counts comparable with those observed in the controls and S-PH patients.
Taken together these data suggest the presence of a distinctive angiogenic phenotype associated with PMF-PAH. However, our small sample size does not allow us to draw any definite conclusions, and larger studies are required to confirm this association.
There are other possible explanations of the high prevalence of PAH in PMF. It has been reported that thrombocytosis is associated with PAH and that this may be due to platelet-derived cytokines such as TGFb and PDGF. Our data regarding the serum concentrations of these cytokines do not add any further insights into this connection, and additional studies are necessary.
It has been reported that pulmonary myeloid metaplasia is associated with PAH development, and that pulmonary radiotherapy is associated with symptom remission. However, unlike the reported cases, our patients did not have severe disease and high-resolution lung CT scan did not show any septal thickening. 4 These data suggest that the contribution of pulmonary myeloid metaplasia may vary from case to case.
In conclusion, the results of our study show that angiogenic parameters are influenced by sPAP levels, thus supporting the concept that PAH is a complication associated with the pro-angiogenic status of PMF. In addition, the relative EPC insufficiency characterizing our patients with PMF-related PAH supports the idea that these cells may play a protective role against this complication. Nilotinib is a new phenylaminopyrimidine with enhanced activity and selectivity against the Bcr-Abl tyrosine kinase compared with imatinib, and promises to improve upon the treatment of chronic myeloid leukaemia and imatinib-resistant disease. 1, 2 Imatinib is well-tolerated by most chronic myeloid leukaemia patients, with a 5-year overall survival rate in newly diagnosed disease of 89%, although it has been observed that some patients showed an association with altered bone and mineral metabolism. 3 This effect is suggested to be caused by a reduction in osteoclast activity, perhaps due to the inhibition of platelet derived growth factor (PDGF) or receptor for MCSF (FMS) receptors by imatinib. The D802V mutation, which corresponds to D816V of KIT, confers complete resistance to imatinib, 4 and similarly, as shown in Figure 1a , this mutation conferred marked but not complete resistance to nilotinib.
The oncogenic V-Fms receptor is not resistant to imatinib, and Figures 1b and c show that the transformed morphology that is characteristic of rodent fibroblasts that express V-Fms 4,5 is suppressed by nilotinib. Phalloidin staining of actin (Figures 1d  and e) shows that nilotinib suppressed membrane ruffling. Figure 1f shows that M-CSF addition caused phosphorylation of the mature form of human FMS expressed by Rat-2 fibroblasts (compare lanes 1 and 2) , and that pretreatment with 250 or 500 nM nilotinib largely inhibited this process. The major phosphorylated band in Figure 1f is the mature FMS receptor and the higher molecular weight smearing is due to receptor ubiquitination. 4 Figure 1g shows that the phosphorylation of FMS D802VY708F, which is a more stable derivative of FMS D802V that is better suited to biochemical analysis, 6 was not substantially inhibited by nilotinib. Similarly, FMS D802VY708 also exhibited greater resistance to nilotinib than FMS in an in vitro kinase assay (Figure 1h ). The oncogenic D802V mutation causes phosphorylation of both the immature and mature receptor forms, and this occurs constitutively in the absence of M-CSF (Figure 1g) . 4 As expected, nilotinib inhibited the phosphorylation of MAPK and Akt in Rat-2 c-fms fibroblasts in response to M-CSF (Supplementary Figure S1) .
We next assessed the inhibitory effect of nilotinib upon osteoclastogenesis of human mononuclear progenitor cells mobilized from bone marrow. Figure 2a shows a representative photograph of human osteoclasts, which have multiple nuclei and a distinctive actin ring. Progenitor cells were grown in 96-well trays in triplicate with M-CSF and RANKL and the indicated concentrations of nilotinib (Figure 2b ). After 2 weeks the cells were stained for TRAP and TRAP-positive osteoclasts with three or more nuclei were counted. Figure 2b shows that nilotinib inhibited osteoclastogenesis with an IC 50 value of 50 nM; similar IC 50 values were obtained in two further experiments. By contrast, in the same experiments imatinib had an IC 50 value of 600 nM for the inhibition of osteoclastogenesis, which is in accord with a previous report. 7 Figure 2c illustrates that pit formation by osteoclasts grown on dentine slices was inhibited by nilotinib or imatinib, as expected. Imatinib can induce the apoptosis of mature osteoclasts 8 and Figure 2d shows that nilotinib has a similar effect at concentrations in the 500-1000 nM range. Figure 2e shows that imatinib and nilotinib had similar inhibitory profiles of macrophage colony formation by murine bone marrow mononuclear (BMM) in response to M-CSF. Figure 2f models the docking of nilotinib into the recently determined structure of the inactive kinase domain of FMS. 9 The predicted binding pose of nilotinib in the FMS active site is supported by the fact that it predicts four hydrogen-bond
